Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography

Cancer Science

Volumn 103, Issue 3, 2012, Pages 600-605

  Achmad, Arifudin ^a   Hanaoka, Hirofumi ^a   Yoshioka, Hiroki ^a   Yamamoto, Shinji ^a   Tominaga, Hideyuki ^a   Araki, Takuya ^a   Ohshima, Yasuhiro ^b   Oriuchi, Noboru ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN ATOMIC ENERGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; TETRAXETAN; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ANTINEOPLASTIC AGENT; COPPER; DIAGNOSTIC AGENT; INDIUM; KRAS PROTEIN, RAT; MONOCLONAL ANTIBODY; PROTEIN P21; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; ONCOGENE K RAS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL STRAIN HT29; COLORECTAL TUMOR; FEMALE; GENETICS; METHODOLOGY; MUTATION; POLYMERASE CHAIN REACTION; RAT; SCINTISCANNING; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HT29 CELLS; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MUTATION; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS P21(RAS); RADIOPHARMACEUTICALS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84859699116     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02166.x     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Van Cutsem E, Nordlinger B, Cervantes A; on behalf of the ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010; 21(Suppl 5): v93-7.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA-Cancer J Clin 2010; 60: 277-300.
4. Engstrom PF, Arnoletti JP, Benson AB et al. Colon Cancer. J Natl Compr Canc Netw 2009; 7: 778-831.
5. Liu L, Cao Y, Tan A, Liao C, Gao F. Cetuximab-based therapy versus noncetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemoth Pharm 2010; 65: 849-61.
6. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
7. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
8. Spano JP, Lagorce C, Atlan D et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16: 102-8.
9. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
10. Italiano A, Follana P, Caroli FX et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15: 649-54.
11. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
12. Katsios C, Ziogas DE, Roukos DH. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol 2010; 4: 525-9.
13. Van Cutsem E, Kohne C, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
14. van Houdt WJ, Hoogwater FJ, de Bruijn MT et al. Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. Neoplasia 2010; 12: 443-52.
15. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: antiepidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154: 37-49.
16. De Hertogh G, Geboes KP. Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy. Arch Pathol Lab Med 2010; 134: 853-63.
17. Campanella C, Mottolese M, Cianciulli A et al. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med 2010; 8: 36.
18. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009; 50: 1116-23.
19. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008; 14: 2983-98.
20. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol I 2007; 34: 850-8.
21. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46: 1898-906.
22. 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008; 23: 158-71.
23. Milenic DE, Wong KJ, Baidoo KE et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23: 619-32.
24. 86Y-CHX-A---DTPA-cetuximab. Eur J Nucl Med Mol I 2010; 37: 1368-76.
25. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009; 50: 123-31.
26. Francoual M, Etienne-Grimaldi MC, Formento JL et al. EGFR in colorectal cancer: more than a simple receptor. Ann Oncol 2006; 17: 962-7.
27. Defize LH, Boonstra J, Meisenhelder J et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989; 109: 2495-507.
28. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 2009; 42: 832-41.
29. 64Culabeled trastuzumab PET. Cancer Sci 2010; 101: 1045-50.
30. 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011; 102: 117-21.
31. 64Cu-labeled chimeric anti-EGFR monoclonal antibody cetuximab for PET imaging of prostate cancer. J Nucl Med 2006; 47(Suppl 1): 107P.
32. 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49: 1472-9.
33. Araki T, Shimizu K, Nakamura K et al. Usefulness of peptide nucleic acid (PNA)-Clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS Codon12 mutations in lung adenocarcinoma: comparison of PNA-Clamp SmartAmp2 and PCR-related methods. J Mol Diagn 2010; 12: 118-24.
34. Distribution of somatic mutations in KRAS. COSMIC Database, Sanger Institute. [Cited 21 Feb 2011.] Available from URL: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=bygene&ln=KRAS.
35. Goetz M, Ziebart A, Foersch S et al. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. Gastroenterology 2010; 138: 435-46.
36. Manning HC, Merchant NB, Foutch AC et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008; 14: 7413-22.
37. Kurai J, Chikumi H, Hashimoto K et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-61.
38. Philpott GW, Schwarz SW, Anderson CJ et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995; 36: 1818-24.
39. 89Zrlabeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009; 50: 1828-36.